Introduction
============

Although lung malignancies are the second most common type of cancers, they are consistently the main cause of malignancy-related mortality in the world (in about 14% of all cases). The lung cancer incidence estimated by the American Society of Clinical Oncology (ASCO) for USA in 2018 is 234,030 new cases (121,680 in men and 112,350 in women), with mortality estimated at 154,050 (including 83,550 men and 70,500 women).[@b1-cmar-10-6555] During the past 15 years, the approach to treat non-small-cell lung cancer (NSCLC) cases has changed from "chemo-for-all" to the use of a "tailored medicine" strategy. Oncologists now have identified that at least one driver change, including gene mutation, rearrangement, or amplification, occurs in 50% of the cases of metastatic lung adenocarcinoma.[@b2-cmar-10-6555],[@b3-cmar-10-6555]

Chromosomal rearrangement has a role in the activation of tyrosine kinase inhibitor (TKI; anaplastic lymphoma kinase \[ALK\]), which leads to the expression of "EML4-ALK" as an "oncogenic fusion kinase."[@b4-cmar-10-6555],[@b5-cmar-10-6555] Additional ALK gene changes similarly happen in anaplastic large-cell lymphoma,[@b6-cmar-10-6555] pediatric neuroblastoma,[@b7-cmar-10-6555] and inflammatory myofibroblastic tumors.[@b8-cmar-10-6555]

For patients having advanced NSCLC with ALK-positive subtypes, new treatment options have been developed using ALK gene rearrangement studies confirmed by "Food and Drug Administration (FDA)-approved tests". Currently, the FDA has granted different levels of approval for the various small molecule TKIs developed for the management of NSCLC with different ALK rearrangements, in that these agents confer different levels of clinical improvement in comparison to standard chemotherapy.

Crizotinib as a TKI has been approved for the management of cancers utilizing tyrosine kinases such as ALK,[@b5-cmar-10-6555] MET,[@b9-cmar-10-6555] or ROS1[@b10-cmar-10-6555] since August 2011, when the FDA recog-nized it as a first-generation ALK inhibitor for treating such cases.[@b10-cmar-10-6555] After 2 years, regular approval for crizotinib was granted by the FDA.

In the cases where ALK rearrangements occurred, leading to disease recurrence or progression after crizotinib treatment, the second- and third-generation oral ALK inhibitors (such as ceritinib, alectinib, or brigatinib) have been approved.[@b11-cmar-10-6555]--[@b13-cmar-10-6555] These newer inhibitors have more potent effects against the different EML4-ALK resistance point mutations.

Based on the ALEX trial, in November 2017, alectinib was approved by the FDA for the management of NSCLC in ALK-positive cases.[@b14-cmar-10-6555] In February 2018, the FDA announced the auditing of another application (for lorlatinib, a third-generation ALK inhibitor) regarding the ability to resensitize cancer cells to crizotinib.[@b15-cmar-10-6555]

Patients and methods
====================

This chart review "retrospective" study focused on the outcomes of advanced NSCLC "stage IIIB and IV" diagnosed at the oncology departments of the Kuwait Cancer Control Center (KCCC) in Kuwait and the King Fahad Specialist Hospital (KFSH) in Saudi Arabia between January 2013 and September 2017. All cancer diagnoses were confirmed by surgical pathology from tissues obtained from either primary lung lesions or metastatic sites. Each diagnosis of adenocarcinoma thus was confirmed by immunohistochemistry (IHC) by an expert pathologist. Evaluations of EGFR mutations, ALK rearrangements, and ROS1 rearrangements were carried out to identify potentially targetable drive alterations. The ALK FISH gene rearrangement evaluation was performed in all patients centrally using CE-marked Vysis LSI ALK Break Apart Rearrangement Probe Kits (Abbott Laboratories, Abbott Park, IL, USA) that detect ALK locus rearrangements on chromosome 2p23.

Patient characteristics, such as age; sex; comorbidities; initial symptoms; metastatic site; prior therapy including surgery, chemotherapy, crizotinib, and local treatment by radiotherapy (RT); response to therapy; pattern of failure; time to progression (TTP); and survival outcome, were documented. All cases had initial staging by "computed tomography (CT) and/or magnetic resonance imaging (MRI) scans" prior to starting crizotinib. Platinum combination chemotherapy was allowed as the first-line treatment. Palliative RT was given at any time to control localized pain or for hemostatic purposes using three-dimensional (3D) conformal RT.

All patients were given crizotinib either as the first-line treatment and/or subsequent treatment upon failure of platinum-based chemotherapy or as a switch maintenance after achieving the maximum response on platinum-based chemotherapy. Crizotinib was recommended as standard dose "250 mg orally every 12 hours with or without meal" until treatment failure or intolerable therapy-related side effects. Dose modification was allowed according to patient tolerance.

Outpatient treatment was carried out with regular evaluation during visits by clinical and laboratory assessment including complete blood counts (CBCs), liver and renal function tests, bone panels, and electrocardiograms. Evaluations of the response were carried out by repeating the CT and/or MRI scans by 3--4-month interval. The response status was recorded according to RECIST 1.0 criteria (Response Evaluation Criteria in Solid Tumors). In the case of solitary recurrence, metastasectomy, stereotactic, and/or gamma knife therapy were performed.

Statistical analyses
====================

Statistical evaluations were carried out by SPSS software version 23.0 (IBM Corporation, Armonk, NY, USA).

All the following are considered as per standard guidelines: response duration, time to objective response (TOR), overall survival (OS), and progression-free survival (PFS). For patients without disease progression at the time of analysis, the date of the last follow-up was considered right censored. Log-rank tests were used for comparisons of the Kaplan--Meier survival curves. All tests of hypotheses were conducted at the alpha of 0.05 level with a 95% CI.[@b16-cmar-10-6555]

Results
=======

We identified 386 adult patients diagnosed by histopathology and IHC with advanced-stage lung adenocarcinoma treated between January 2013 and September 2017 at both centers. We identified ALK rearrangement in 38 of these using FISH. The median age of the study subjects was 53 years (41--82), with five patients above 65 years and a male predominance (70.8%). Nonsmokers composed more than half of the patients (57.9%). The majority of patients (36 patients; 94.7%) had a good performance status (PS) according to "Eastern Cooperative Oncology Group (ECOG)". One patient had an ECOG PS of 3 due to an extensive lumber vertebral metastasis that needed fixation and postoperative irradiation. He moved with the assistance of a walker or by wheelchair. Another patient had ECOG PS of 4, on mechanical ventilation secondary to respiratory failure, and we initiated crizotinib therapy through a nasogastric tube.[@b17-cmar-10-6555]

Five patients (13.2%) had stage IIIB disease, while the rest (86.8%) had stage IV disease, of whom 11 patients (28.9%) were diagnosed with a single-site metastasis. A pretreatment staging workup identified that bones (24.1%), liver (23.7%), and brain (21.1%) were the most common sites for metastases ([Table 1](#t1-cmar-10-6555){ref-type="table"}). Three patients (7.9%) were known to have NSCLC after lobectomy for early-stage disease. At follow-up, these patients had developed distant metastases. Biopsies from the metastatic sites confirmed ALK-positive disease.

Treatment received, treatment interruptions, and dose modification
------------------------------------------------------------------

More than half of the patients (55.3%) were treated with a platinum-based combination at some point before crizotinib initiation, either as a postoperative adjuvant therapy or as a palliative therapy for a metastatic disease before the availability of the ALK testing results. A wide variety of platinum-based combinations were used: pemetrexed, paclitaxel, gemcitabine, or vinorelbine plus a platinum component with/without bevacizumab. Before the initiation of crizotinib, seven patients (18.4%) received palliative RT either as a whole brain irradiation for multiple brain metastases, for palliation of tender bony metastasis, or as a hemostatic dose. Three patients (7.9%) were treated for solitary brain metastasis by gamma knife brain surgery.

On the initiation of crizotinib, the majority of patients (32 patients; 84.2%) tolerated the 250 mg oral (PO)/BID dose with no significant interruptions. Treatment interruptions and dose modification were recommended by the treating physician for six patients (15.8%) because of intolerable adverse events ([Table 2](#t2-cmar-10-6555){ref-type="table"}).

Failure of crizotinib was reported in 16 patients (42.1%), of whom 15 patients had clinical and radiological disease progression on crizotinib. During crizotinib therapy, intracranial relapse with a limited number of brain lesions occurred in four patients. These patients had good extracranial disease control and continued on crizotinib therapy after controlling the intracranial relapse; two patients (12.5%) received gamma knife brain therapy, one patient (6.3%) received stereotactic brain surgery, and another patient underwent a craniotomy ([Table 3A](#t3-cmar-10-6555){ref-type="table"}).

Adverse events were recorded in 38 patients and are summarized in [Table 3B](#t3-cmar-10-6555){ref-type="table"}. The most commonly reported events were fatigue (68.4%), peripheral edema (63.2%), and transaminitis (50%). Grade III transaminitis occurred in two patients. After a few days of treatment, enzyme titers returned to basal levels and crizotinib was resumed and continued at a lower dosage (200 mg orally twice daily) without further interruptions. Grade IV transaminitis was reported in another patient. After normalization of the hepatic enzymes, this patient was changed to alectinib treatment, but unfortunately, the same adverse event was reported. Finally, this patient commenced chemotherapy and showed a good tolerance to it.

Diarrhea (grade III/IV) occurred in three of the cases (7.9%), leading to dehydration and a slight elevation of blood urea nitrogen in one patient. Uncomplicated neutropenia was reported in six patients (15.8%).

Bradycardia with prolonged QT interval occurred in 10 patients (26.3%). Three were grade III/IV. One of these patients was a 72-year-old female, who was morbidly obese, with a cardiac pacemaker implanted for the previous 7 years. On day 9 of crizotinib usage, she fainted and was found to have severe sinus bradycardia (heart rate was 30 beats/min) and significant prolongation of the QT interval. She was admitted to a cardiac care unit where crizotinib was immediately stopped. After 3 days of monitoring, her heart rate returned to her baseline level. Because of her advanced age, multiple comorbidities, and her advanced cancer with expected poor tolerance to chemotherapy, our thoracic multidisciplinary team and her cardiologist adjusted the pacemaker to a higher rate and resumed crizotinib at 250 mg PO BID. Another two patients, with unknown history of cardiac disease, developed sinus bradycardia and prolongation of the QT interval. They showed good tolerance on the lower dosage.

Of the 38 patients included in efficacy analyses, 36 were suitable for response evaluation (two patients died early from the disease). The objective response rate (ORR) was 50%. Two cases (5.3%) were with a complete response (CR), and 17 cases (44.7%) were with a partial response (PR). Two cases (5.3%) achieved stable disease (SD), while progressive disease (PD) occurred in four cases (16.7%). The median time to an objective response in 19 patients was 3.4 months (range 2.2--5.2 months, 95% CI: 3.2--3.7). The time of the response was 19.9 months.

The 1-year survival rate was 88.6%, while 5-year survival rate was 34.8%. The mean PFS was 17.678± 4.227 months (rang: 9.393- 25.963). Patients with first -line crizotinib had a lower mean PFS of 14.834 ± 6.789 months (range: 1.527--28.141) when compared to the patients who received crizotinib as a subsequent line of treatment with PFS of 20.928±4.958 months (range: 11.210--30.646) with no statistically significant outcome (*P*=0.487).

The mean OS was 50.097±6.547 months (rang: 37.265--62.928 months). Patients with first-line crizotinib treatment had longer mean OS of 48.794 ±8.941months (rang: 31.270--66.319 months) when compared to patients who received crizotinib as subsequent lines with mean OS of 46.790±7.827 months (range: 48.794--62.131) with no statistically significant outcome (P=0.456) ([Table 4](#t4-cmar-10-6555){ref-type="table"} and [Figures 1](#f1-cmar-10-6555){ref-type="fig"} and [2](#f2-cmar-10-6555){ref-type="fig"}).

Discussion
==========

Worldwide, lung cancer has been described as the highest malignancy as per public health view. In Kuwait, lung cancer is the sixth most frequent cancer (6.2% of all malignancies, the fifth most common in males and the ninth in females). Lung cancer is the most common reason for malignancy-related mortality (15.9%) in Kuwaiti males, while among Kuwaiti females, it is the fifth most common reason for malignancy-related mortality (4.9%). In Saudi Arabia, lung cancer is the sixth most frequent cancer (4.7% for all malignancies). In Saudi males, lung cancer is the fourth highest malignancy (7.4%) and the second most common cause of malignancy-related mortality (11.2%). Lung cancer in Saudi females is very rare (2.2%), and it is the eighth most common cause of malignancy-related mortality (4.4%).[@b18-cmar-10-6555]

The OS is the most consistent end point in estimating any investigational new treatment for cancer, with significant progress in OS needed for getting regulatory approval. Post approval, local research is important as well to assess the drug's effectiveness and tolerability.

We performed a retrospective study on the management of cases confirmed as advanced-stage ALK-positive NSCLC. This study used existing data available in the medical charts and electronic medical records of two of the biggest tertiary referral centers for cancer management on the western coast of the Arabian Gulf, the KCCC and the KFSH, from January 2013 to September 2017.

Crizotinib is a first-generation ALK-TKI that has previously been shown to have remarkable activity for the treatment for ALK-positive NSCLC, considering the response rate and PFS results. In August 2011, crizotinib was approved by the FDA for the management of ALK-positive advanced-stage NSCLC based on the outcomes of the PROFILE 1014 trial, where crizotinib showed superiority to the first pemetrexed/platinum combination in cases with advanced ALK-positive NSCLC not previously treated. Treatment with crizotinib resulted in longer PFS, higher ORR, and more tolerable adverse events than chemotherapy.[@b19-cmar-10-6555] Although there were fewer subjects in our study than in the PROFILE 1014 trial (38 vs 172 subjects), there were some differences. We detected ALK rearrangement in 9.8% of cases of lung adenocarcinoma, while in most of the published studies, ALK rearrangement was reported in 5--7% of cases.[@b4-cmar-10-6555],[@b5-cmar-10-6555] Most of the subjects in our study were young, Asian, and nonsmoker females, and this may explain the high prevalence of ALK-positive NSCLC in our study. The median age of our cases was 53 years, and most of these cases were nonsmokers (57.9%).

Similar results were shown in the PROFILE 1014 trial (age 52 years, and 65% nonsmokers). Because of the toxicity profiles of all the approved ALK-TKIs used in clinical practice, we were able to administer crizotinib via nasogastric tube in a patient with poor PS (ECOG PS 3--4).[@b17-cmar-10-6555]

At the time of initial diagnosis, central nervous system (CNS) metastasis was reported in 21.1% of our patients vs 38% in the PROFILE 1014 trial. The strategy we applied for controlling CNS disease is supported by the results of this trial, including the effects of whole-brain irradiation, gamma knife brain surgery, stereotactic brain surgery, craniotomy, and following up of asymptomatic small brain lesions.[@b20-cmar-10-6555]

In the PROFILE 1014 trial, the ORR for crizotinib was 74%. The median PFS was extended more with crizotinib than with chemotherapy "10.9 vs 7.0 months". The median OS was not reached by crizotinib; the likelihood of 1-year survival with crizotinib was stable at 84%. In our study, the ORR for crizotinib was 50%, and the median PFS was 16.5 months (95% CI: 1.6--31.4). The median OS from the initiation of crizotinib was 48.0 months (95% CI: 18.2--77.8). In the near future, ALK mutation analysis may play a role in explaining why some ALK-positive NSCLC patients do not respond well to crizotinib.[@b21-cmar-10-6555]

When the use of standard chemotherapeutic agents results in clinical failure, it is feasible to switch to crizotinib as per prior first- and second-line registration trials of crizotinib. In our study, the survival differences between the cases that received standard chemotherapy before and chemotherapy-naive cases were challenging based on the confounding factors involved in patient selection and previous chemotherapy exposure. Our analysis revealed no substantial difference in PFS (*P*-value was 0.49) or OS (*P*-value was 0.46) between cases exposed to standard platinum-based combination chemotherapy before crizotinib and those who received crizotinib as the first-line treatment. These differences could be elucidated in a randomized controlled study.[@b22-cmar-10-6555]

Lee et al[@b23-cmar-10-6555] concluded in their study that ALK positivity was unconventionally predictive of pemetrexed effectiveness in NSCLC cases. ALK-positive crizotinibnaive patients have a significantly longer PFS when receiving pemetrexed.

Conclusion
==========

Crizotinib seems to be a promising agent for the management of advanced ALK-positive NSCLC. Crizotinib had a good response rate, a very acceptable side effect profile, promising median PFS, and median OS.
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**Notes:** (**A**) The mean PFS was 17.678±4.227 months (range: 9.393--25.963). (**B**) The 1-year survival was 88.6% and 5-year survival as 34.8%.The mean OS was 50.097±6.547 months (rang: 37.265--62.928).\
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![Kaplan--Meier estimates of survival functions stratified by prior platinum-based chemotherapy in intention-to-treat population.\
**Notes:** (**A**) Patients with first line crizotinib had less mean PFS of 14.834±6.789 months (range: 1.527--28.141) and patients received crizotinib as subsequent lines with PFS of 20.928±4.958 months with no statistically significant outcome (*P*=0.487). (**B**) Patients with first line crizotinib had longer mean OS of 48.794±8.941months and patients received crizotinib as subsequent lines with OS of 46.790±7.827 months with no statistically significant outcome (*P*=0.456).\
**Abbreviations:** OS, overall survival; PFS, progression-free survival.](cmar-10-6555Fig2){#f2-cmar-10-6555}

###### 

Patient characteristics at baseline (n=38)

  Parameter                        N (%)
  -------------------------------- -------------
                                   
  **Median age (range), years**    53 (41--82)
                                   
  **Gender, n (%**)                
   Male                            25 (65.8)
   Female                          13 (34.2)
                                   
  **Race**                         
   Arab                            28 (73.7)
   Non-Arab                        10 (26.3)
                                   
  **Smoking status**               
   Current or former smoker        10 (26.3)
   Never smoker                    22 (57.9)
   Ex-smoker                       6 (15.8)
                                   
  **Comorbidities**                
   Hypertension                    15 (39.5)
   Diabetes                        16 (42.1)
   Cardiac                         6 (15.8)
   Renal impairment                5 (13.2)
   Obese (BMI ≥30 kg/m^2^)         4 (10.5)
                                   
  **ECOG PS**                      
   0                               10 (26.3)
   1                               21 (55.3)
   2                               5 (13.2)
   3                               1 (2.6)
   4                               1 (2.6)
                                   
  **Major symptoms**               
   Shortness of breath             24 (63.2)
   Weight loss                     18 (47.4)
   Pain                            9 (23.7)
   Headache                        5 (13.2)
                                   
  **TNM stage**                    
   Stage IIIB                      5 (13.2)
   Stage IV                        33 (86.8)
                                   
  **Number of metastatic sites**   
   Multiple sites                  22 (57.9)
   Single                          11 (28.9)
                                   
  **Sites of metastasis**          
   Bone                            16 (24.1)
   Liver                           9 (23.7)
   Brain                           8 (21.1)
   Abdominal lymph nodes           8 (21.1)
   Adrenal(s)                      7 (18.4)
   Contralateral lungs             4 (10.5)

**Abbreviations:** BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; PS, performance status.

###### 

Treatment received, interruptions, and dose modifications

  Parameter                                       N (%)                         
  ----------------------------------------------- ----------------------------- -----------
                                                                                
  Prior therapy                                   Platinum-based chemotherapy   21 (55.3)
  RT                                              7 (18.4)                      
  Primary tumor resection                         3 (7.9)                       
  Gamma knife brain therapy                       3 (7.9)                       
                                                                                
  Concurrent therapy                              RT                            5 (13.2)
  Gamma knife brain therapy                       2 (5.3)                       
  Craniotomy                                      1 (2.6)                       
  Stereotactic brain surgery                      1 (2.6)                       
                                                                                
  Crizotinib timing                               First line                    20 (52.6)
  Subsequent line                                 18 (47.4)                     
                                                                                
  Crizotinib dosage                               250 mg twice daily            32 (84.2)
  200 mg twice daily                              6 (15.8)                      
                                                                                
  Treatment interruptions                         Yes                           8 (21.1)
  No                                              30 (78.9)                     
                                                                                
  Line of treatment after failure on crizotinib   Another TKI                   9 (60.0)
  Chemotherapy                                    5 (33.3)                      
  BSC                                             1 (6.7)                       

**Abbreviations:** BSC, best supportive care; RT, radiotherapy; TKI, tyrosine kinase inhibitor.

###### 

Crizotinib failure and adverse events (38 patients)

  \(A\) Crizotinib failure (16 patients)                               
  ------------------------------------------------- ------------------ ------------------
  Pattern of failure                                Oligo metastasis   2 (12.5)
  Multiple metastasis only                          6 (37.5)           
  Locoregional only                                 3 (18.7)           
  Locoregional and distant metastasis               4 (25.0)           
  Poor tolerance to treatment                       1 (6.3)            
  Intracranial relapse 5 (13.1)                                        
  **(B) Crizotinib adverse events (38 patients)**                      
  **Parameter**                                     **Any grade**      **Grade III/IV**
  Fatigue                                           26 (68.4)          1 (2.6)
  Peripheral edema                                  24 (63.2)          2 (5.3)
  Transaminitis                                     19 (50.0)          3 (7.9)
  Skin changes                                      14 (36.8)          0 (0.0)
  Diarrhea                                          12 (32.6)          3 (7.9)
  Bradycardia                                       11 (28.9)          0 (0.0)
  Prolonged QT                                      10 (26.3)          3 (7.9)
  Colored vision                                    8 (21.1)           0 (0.0)
  Nausea/vomiting                                   7 (18.4)           0 (0.0)
  Neutropenia                                       6 (15.8)           0 (0.0)
  Neuropathy                                        6 (15.8)           0 (0.0)
  Constipation                                      3 (7.9)            0 (0.0)

###### 

Response and survival outcome

  ---------------------------------------------------------------------
  Parameter   N                        \%                   
  ----------- ------------------------ -------------------- -----------
                                                            

  Response    **Evaluated patients**   **36**               **94.7%**

              CR                       2                    5.3%

              PR                       17                   44.7%

              SD                       2                    5.3%

              PD                       15                   39.5%

                                                            

              **Nonevaluated**         2 (5.3%)             

                                                            

              **Median TOR**           **3.4 months**\      
                                       (range: 2.2--5.2)\   
                                       (95% CI: 3.2--3.7)   

                                                            

  Survival    **1-year survival**      **88.6%**            

              **5-year survival**      **34.8%**            
  ---------------------------------------------------------------------

**Abbreviations:** CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease; TOR, time to objective response.
